Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cut price Herceptin and MabThera in India could set Roche's emerging market strategy

This article was originally published in Scrip

Executive Summary

Roche will be partnering up with the Indian firm Emcure to launch reduced price versions of its anticancers Herceptin (trastuzumab) and MabThera (rituximab) in India. The move has nothing to do with India's decision to issue a compulsory license for Bayer's anticancer, Nexavar (sorafenib tosylate), but is instead more of a pilot for reaching lower income patients in emerging markets, the firm told Scrip.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts